Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 3752.

https://doi.org/10.1182/blood-2024-211475

Published: 2024

Journal Articles

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2024-201810

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4393.

https://doi.org/10.1182/blood-2024-193091

Published: 2024

Journal Articles

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Pooja Phull, Noa Biran, David H. Vesole, Harsh Parmar, Andrew L Pecora, Andrew Ip, Andre Goy, David S. Siegel

Blood (2024) 144 (Supplement 1): 3316.

https://doi.org/10.1182/blood-2024-203774

Published: 2024

Journal Articles

Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

Maher Albitar, Hong Zhang, Sally Agersborg, Ahmad Charifa, Andrew L Pecora, Lori A. Leslie, Tatyana Feldman, Andrew Ip, Andre Goy

Blood (2024) 144 (Supplement 1): 4367.

https://doi.org/10.1182/blood-2024-203834

Published: 2024

Journal Articles

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Blood (2024) 144 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2024-212274

Published: 2024

Journal Articles

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Maher Albitar, Sally Agersborg, Ahmad Charifa, Hong Zhang, Andrew Ip, Katherine Linder, Andrew L Pecora, Jamie Koprivnikar, Andre Goy, James McCloskey

Blood (2024) 144 (Supplement 1): 4295.

https://doi.org/10.1182/blood-2024-203870

Published: 2024

Journal Articles

Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)

Maciej Kabat, Vanisha Patel, Sukhdeep Kaur, Michael Pelliccia, Charles Zhao, Patrick Roney, Alexandra Della Pia, Jaeil Ahn, David H. Vesole, Michele L. Donato, Hyung C Suh, Christina Cho, Pritish K. Bhattacharyya, Scott D Rowley, Andrew Ip

Blood (2024) 144 (Supplement 1): 7413.

https://doi.org/10.1182/blood-2024-204093

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Blood (2024) 144 (Supplement 1): 238.

https://doi.org/10.1182/blood-2024-192995

Published: 2024

Journal Articles

Evaluating the Survival Impact of Different Treatment Modalities in Gastric Marginal Zone Lymphoma Based on Tumor Stage: A SEER Database Analysis

Ayrton I Bangolo, Lili Zhang, Vignesh K Nagesh, Andrew Ip, Behzad Amoozgar

Blood (2024) 144 (Supplement 1): 6290.

https://doi.org/10.1182/blood-2024-202424

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7760.

https://doi.org/10.1182/blood-2024-203876

Published: 2024

Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Blood (2024) 144 (Supplement 1): 7757.

https://doi.org/10.1182/blood-2024-203540

Published: 2024

Journal Articles

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Mimi Chen, Wenbin Mo, Gennaro Clando, Yuanyuan Tian, Ciril Abraham, Qingrong Huang, Ying WANG, Morgan Chaunzwa, Yan Zhou, Andrew Ip, Andre Goy, Jaroslav Jelinek, Jozef Madzo, Jean-Pierre Issa, Yi Zhang

Blood (2024) 144 (Supplement 1): 2039.

https://doi.org/10.1182/blood-2024-207438

Published: 2024

Journal Articles

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Beatriz Wills, Roni Shouval, Jessica R. Flynn, Sean M. Devlin, Allison Parascondola, Amethyst Saldia, Brandon S. Imber, Ana Alarcon Tomas, Ivan Landego, Richard J. Lin, Michael Scordo, Parastoo Bahrami Dahi, Gunjan L. Shah, Andrew Ip, Lori A Leslie, Hyung Chan Suh, Gilles Salles, Miguel-Angel Perales, Maria Lia Palomba

Blood (2023) 142 (Supplement 1): 3014.

https://doi.org/10.1182/blood-2023-181116

Published: 2023

Journal Articles

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2023-189349

Published: 2023

Journal Articles

Outcomes Analysis of Lenalidomide-Induced Rashes in Myeloma Patients

James Behrmann, Robert J Vanaria, Shannon Meledathu, Aishwarya Sridhar, Michael Povelaitis, Harsh Parmar, Andrew Ip

Blood (2023) 142 (Supplement 1): 6689.

https://doi.org/10.1182/blood-2023-184906

Published: 2023

Journal Articles

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

Tatyana Feldman, Alexandra Della Pia, Geeny Lee, Thomas S. Gunning, Michael Pelliccia, Tony Varughese, Harsh Parmar, Andrew Ip, Lori A. Leslie, Andre Goy, Samuel Singer

Blood (2023) 142 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2023-187164

Published: 2023

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Geoffrey P. Shouse, Kristie A. Blum, Julie E. Haydu, Jeremy S. Abramson, Mayur Narkhede, Andrew Ip, Jennifer S. Michaelson, Patrick A. Baeuerle, Kristan Meetze, Irina Shapiro, Todd Shearer, Judith Inumerable, Jeff Jones, Farrukh T. Awan

Blood (2023) 142 (Supplement 1): 3142.

https://doi.org/10.1182/blood-2023-181239

Published: 2023

NARROW

Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma

Clonotype-Naïve Detection of Clonality in Patients Suspected of Having Multiple Myeloma or Monoclonal Gammopathy Using Peripheral Blood Cell-Free RNA (cfRNA)

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Tumor Determinants of Response to CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma

Establishing a Distinct Cytokine Signature for Multiple Myeloma Using Bone Marrow RNA and Peripheral Blood Cell-Free RNA (cfRNA)

Establishing Lymphoma Type-Specific Cytokine Signatures Using Tissue-Based RNA or Peripheral Blood Cell-Free RNA (cfRNA)

CAR T-Cell Therapy for DLBCL with CNS Involvement: Overall Safe and Effective with Limited Efficacy in Patients with Leptomeningeal Disease

Establishing Distinct Cytokine Signatures Differentiating between Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Chip Using Bone Marrow RNA or Cell-Free RNA (cfRNA)

Potential Role of Donor CD3 Chimerism in Predicting Relapse after Allogeneic Transplantation in Patients with Acute Myelogenous Leukemia (AML)

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Treatment Patterns and Outcomes Following Progression of Disease Post-CAR-T Therapy in Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter Analysis

Evaluating the Survival Impact of Different Treatment Modalities in Gastric Marginal Zone Lymphoma Based on Tumor Stage: A SEER Database Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Reprogramming T Cell EZH2 to Counteract CAR T Cell Dysfunction during Tumor Control

Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma

Comparison of Bendamustine Versus Fludarabine/ Cyclophosphamide Lymphodepletion in Adult Patients Receiving CD19 CAR-T Cell Therapy

Outcomes Analysis of Lenalidomide-Induced Rashes in Myeloma Patients

Retrospective Review of Patients Treated with Intrathecal Rituximab for Primary and Secondary CNS Lymphoma and Leukemia

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only